CA3207182A1 - T cell therapy - Google Patents
T cell therapyInfo
- Publication number
- CA3207182A1 CA3207182A1 CA3207182A CA3207182A CA3207182A1 CA 3207182 A1 CA3207182 A1 CA 3207182A1 CA 3207182 A CA3207182 A CA 3207182A CA 3207182 A CA3207182 A CA 3207182A CA 3207182 A1 CA3207182 A1 CA 3207182A1
- Authority
- CA
- Canada
- Prior art keywords
- cell therapy
- immunotherapies
- compositions
- methods
- prognosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title 1
- 238000002659 cell therapy Methods 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
Abstract
The disclosure relates to methods of diagnosis and prognosis, compositions for immunotherapies, methods of improving said compositions, and immunotherapies using the same.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163135711P | 2021-01-10 | 2021-01-10 | |
US63/135,711 | 2021-01-10 | ||
PCT/US2022/011606 WO2022150582A1 (en) | 2021-01-10 | 2022-01-07 | T cell therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3207182A1 true CA3207182A1 (en) | 2022-07-14 |
Family
ID=80979083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3207182A Pending CA3207182A1 (en) | 2021-01-10 | 2022-01-07 | T cell therapy |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220221463A1 (en) |
EP (1) | EP4275044A1 (en) |
JP (1) | JP2024502599A (en) |
KR (1) | KR20230129485A (en) |
CN (1) | CN116917737A (en) |
AU (1) | AU2022205653A1 (en) |
CA (1) | CA3207182A1 (en) |
IL (1) | IL304155A (en) |
TW (1) | TW202238129A (en) |
WO (1) | WO2022150582A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024092152A1 (en) * | 2022-10-28 | 2024-05-02 | Kite Pharma, Inc. | Improving efficacy and durable response of immunotherapy |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
US6406699B1 (en) | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
JP2004500095A (en) | 2000-02-24 | 2004-01-08 | エクサイト セラピーズ, インコーポレイテッド | Simultaneous stimulation and enrichment of cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
GB0700058D0 (en) | 2007-01-03 | 2007-02-07 | Scancell Aps | Anti-tumor vaccine based on normal cells |
CN106220739A (en) | 2010-12-09 | 2016-12-14 | 宾夕法尼亚大学董事会 | The purposes of the T cell treatment cancer that Chimeric antigen receptor is modified |
BR112013018311A2 (en) | 2011-01-18 | 2017-03-21 | Univ Pennsylvania | isolated nucleic acid sequence, isolated chimeric antigen receptor, genetically modified t cell, vector, and use of a genetically modified t cell. |
KR101976882B1 (en) | 2011-03-23 | 2019-05-09 | 프레드 헛친슨 켄서 리서치 센터 | Method and compositions for cellular immunotherapy |
EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
MX2014003176A (en) | 2011-09-16 | 2015-08-05 | Univ Pennsylvania | Rna engineered t cells for the treatment of cancer. |
US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
JP7197979B2 (en) | 2015-05-28 | 2022-12-28 | カイト ファーマ インコーポレイテッド | Methods of conditioning a patient for T cell therapy |
EP3788369A1 (en) * | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
WO2019232510A1 (en) * | 2018-06-01 | 2019-12-05 | Kite Pharma, Inc. | Chimeric antigen receptor t cell therapy |
EP4106775A4 (en) * | 2020-02-20 | 2024-03-06 | Kite Pharma Inc | Chimeric antigen receptor t cell therapy |
-
2022
- 2022-01-07 KR KR1020237026771A patent/KR20230129485A/en unknown
- 2022-01-07 WO PCT/US2022/011606 patent/WO2022150582A1/en active Application Filing
- 2022-01-07 US US17/570,917 patent/US20220221463A1/en active Pending
- 2022-01-07 EP EP22703734.8A patent/EP4275044A1/en active Pending
- 2022-01-07 AU AU2022205653A patent/AU2022205653A1/en active Pending
- 2022-01-07 JP JP2023541537A patent/JP2024502599A/en active Pending
- 2022-01-07 CN CN202280009485.3A patent/CN116917737A/en active Pending
- 2022-01-07 CA CA3207182A patent/CA3207182A1/en active Pending
- 2022-01-10 TW TW111100953A patent/TW202238129A/en unknown
-
2023
- 2023-06-29 IL IL304155A patent/IL304155A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL304155A (en) | 2023-09-01 |
KR20230129485A (en) | 2023-09-08 |
CN116917737A (en) | 2023-10-20 |
TW202238129A (en) | 2022-10-01 |
EP4275044A1 (en) | 2023-11-15 |
AU2022205653A1 (en) | 2023-07-27 |
US20220221463A1 (en) | 2022-07-14 |
JP2024502599A (en) | 2024-01-22 |
WO2022150582A1 (en) | 2022-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3156451A1 (en) | Antibodies having specificity for nectin-4 and uses thereof | |
WO2018097540A3 (en) | Serum-free immune cell-culturing medium-added kit, method for culturing immune cells by using same kit, serum-free immune cell culture obtained by same kit or culturing method, and cosmetic composition comprising same culture | |
WO2019014395A8 (en) | Generation of water-soluble cannabinoid compounds in yeast and plant cell suspension cultures and compositions of matter | |
EP4302784A3 (en) | Anti-ntb-a antibodies and related compositions and methods | |
WO2019006005A3 (en) | Methods and compositions for treating melanoma | |
GB2548740A (en) | Methods for generation of podocytes from pluripotent stem cells and cells produced by the same | |
MX2022000893A (en) | Method of obtaining mitochondria from cells and obtained mitochondria. | |
WO2021257730A3 (en) | Cells modified by a cas12i polypeptide | |
MX2022001977A (en) | Ex vivo gamma delta t cell populations. | |
WO2020107002A3 (en) | Methods for expansion of natural killer (nk) cell subset and related compositions and methods | |
WO2018170150A3 (en) | Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins | |
MX2023004869A (en) | Antibodies against sars-cov-2 and uses thereof. | |
MX2022005091A (en) | Methods of preparing an enriched sample for polypeptide sequencing. | |
MX2021012041A (en) | Methods of promoting thymic epithelial cell and thymic epithelial cell progenitor differentiation of pluripotent stem cells. | |
MX2022001449A (en) | Human aminosterol ent-03 compounds, related compositions comprising the same, and methods of using the same. | |
WO2019121961A3 (en) | Methods for modulating protein mannosylation profiles using maduramycin, narasin, or salinomycin | |
CA3207182A1 (en) | T cell therapy | |
MX2022001428A (en) | Methods and compositions for culturing hemoglobin-dependent bacteria. | |
WO2018156448A8 (en) | Prediction and treatment of immunotherapeutic toxicity | |
WO2020132027A3 (en) | Cell-free production of allulose | |
WO2019075216A8 (en) | Plectin-1 binding antibodies and uses thereof | |
WO2019066617A3 (en) | Anti-c-met antibody and uses thereof | |
MX2021011609A (en) | Modulators of cell surface protein interactions and methods and compositions related to same. | |
WO2021041324A3 (en) | Compositions and methods for the treatment of pathological pain and itch | |
MX2021008022A (en) | Heterodimeric proteins for modulating gamma delta t cells. |